|
Characteristic
|
Total
|
p-Ser153 RKIP expression
|
|---|
|
(n = 733)
|
Negative
|
Positive
|
P value
|
|---|
|
No.
|
%
|
No.
|
%
|
No.
|
%
|
|---|
|
Age, y(median)
|
|
≤46
|
362
|
49.39
|
164
|
45.3
|
198
|
54.7
|
0.468
|
|
>46
|
371
|
50.61
|
178
|
48.0
|
193
|
52.0
| |
|
Sex
|
|
Male
|
394
|
53.75
|
168
|
42.6
|
226
|
57.4
|
0.019
|
|
Female
|
339
|
46.25
|
174
|
51.3
|
165
|
487
| |
|
N classification
|
|
N0+1
|
377
|
51.43
|
174
|
46.2
|
203
|
53.8
|
0.778
|
|
N2+3
|
356
|
48.57
|
168
|
47.2
|
188
|
52.8
| |
|
T classification
|
|
T1+2
|
438
|
59.75
|
188
|
42.9
|
250
|
57.1
|
0.014
|
|
T3+4
|
295
|
40.25
|
154
|
52.2
|
141
|
47.8
| |
|
TNM classification
|
|
I + II
|
335
|
57.57
|
160
|
47.8
|
175
|
52.2
|
0.583
|
|
III + IVa + b
|
398
|
42.43
|
182
|
45.7
|
216
|
54.3
| |
|
Pathologic classification
|
|
Type I
|
10
|
1.36
|
4
|
40
|
6
|
60
|
0.116
|
|
Type II
|
84
|
11.32
|
48
|
57.1
|
36
|
42.9
| |
|
Type III
|
639
|
87.31
|
290
|
45.4
|
349
|
54.6
| |
|
Survival status
|
|
Yes
|
415
|
56.62
|
130
|
31.3
|
285
|
68.7
|
<0.001
|
|
No
|
318
|
43.38
|
212
|
66.7
|
106
|
33.3
| |
|
Local-regional relapse
|
|
Yes
|
155
|
21.15
|
92
|
59.4
|
63
|
40.6
|
0.001
|
|
No
|
578
|
78.85
|
250
|
43.3
|
328
|
56.7
| |
|
Post-treatment progression
|
|
Yes
|
324
|
44.20
|
197
|
60.8
|
127
|
39.2
|
<0.001
|
|
No
|
409
|
56.80
|
145
|
35.5
|
264
|
64.5
| |
|
Post-treatment distant metastasis
|
|
Yes
|
224
|
30.56
|
125
|
55.8
|
99
|
44.2
|
0.001
|
|
No
|
509
|
69.44
|
217
|
42.6
|
292
|
57.4
| |
